1:53 PM
 | 
May 17, 2019
 |  BC Extra  |  Clinical News

AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

In a second setback for glioblastoma multiforme patients this month, AbbVie said its depatuxizumab mafodotin missed the primary endpoint of improving overall survival in the Phase III INTELLANCE-1 for newly diagnosed EGFR-amplified GBM.

AbbVie Inc. (NYSE:ABBV) management had touted its expectations for the readout in its last two earnings calls. In its January call, Vice Chairman and President Michael Severino pointed to "encouraging trends in overall survival" seen in a Phase II trial of depatuxizumab mafodotin (Depatux-M, formerly ABT-414) to treat GBM in a...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >